Pancreatic Cancer Research

ResearcherUnited States Department of Veterans AffairsActive in the last 2 years

Courtney W. Houchen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2487-5242; OpenAlex author ID A5064340210; NIH RePORTER profile ID 8710262. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 3, last author 6)
Trials
1 (principal investigator on 1)
Grants
4
Labs led
1
Collaborators
72
Papers, trials and grants by year

2010: 1 trial · 2011: 1 paper, 1 grant · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper, 1 grant · 2017: none · 2018: 1 paper · 2019: 1 paper, 1 grant · 2020: 3 papers · 2021: 3 papers, 1 grant · 2022: 6 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 28

  1. Spatial evolution of a cachexia-promoting microenvironment in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.09.012↗
  2. Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5716↗
  3. A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth. Last author DOI 10.1038/s41598-025-19722-z↗
  4. Glutaminase 2-Mediated Yes Associated Protein 1 Glutamylation Facilitates Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.02.029↗
  5. Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy. Co-author DOI 10.1158/1078-0432.ccr-24-4368↗
  6. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Co-author DOI 10.1016/j.ccell.2024.03.009↗
  7. Replication stress identifies novel molecular classification associated with treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.008↗
  8. Attenuating DNA damage response and immunosuppression radiosensitizes pancreatic cancer. First author DOI 10.1016/j.ebiom.2022.103822↗
  9. A Novel Translational Activation of HIF1α Promotes Pancreatic Cancer Growth Through Glycolytic Reprogramming. First author DOI 10.1053/j.gastro.2022.01.040↗
  10. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.02.017↗
  11. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.06.058↗
  12. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-22-1083↗
  13. Reg4 Interacts with CD44 to Regulate Proliferation and Stemness of Colorectal and Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-21-0224↗
  14. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  15. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
  16. Interplay of Tumor Microenvironment Factors and Cancer Stem Cell Enrichment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.09.024↗
  17. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Co-author DOI 10.1053/j.gastro.2019.10.038↗
  18. Tuft Cells Play Critical Roles in the Heterogeneity and Epithelial Plasticity in Pancreatic Cancer Initiation and Progression. Last author DOI 10.1053/j.gastro.2020.09.004↗
  19. A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma. Co-author DOI 10.1186/s12916-020-01620-y↗
  20. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cance… Last author DOI 10.1155/2019/6402925↗
  21. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Co-author DOI 10.1158/1078-0432.ccr-18-0263↗
  22. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Co-author DOI 10.18632/oncotarget.6819↗
  23. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Last author DOI 10.1371/journal.pone.0118933↗
  24. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.3499↗
  25. ZIP4 silencing improves bone loss in pancreatic cancer. Co-author DOI 10.18632/oncotarget.4667↗
  26. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase… Last author DOI 10.1186/1476-4598-13-103↗
  27. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. Last author DOI 10.1371/journal.pone.0073940↗
  28. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0016958↗

Trials 1

  1. Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer Principal investigator NCT01580241↗

Grants 4

  1. The role of Dclk1 in the initiation of colorectal cancer R01CA214017↗
  2. The role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma R01CA182869↗
  3. Targeting DCLK1 kinase activity in pancreatic cancer R21CA186175↗
  4. Pancreatic Stem Cells and Cancer R21CA137482↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Li · 17 shared papers, 2015–2026 · strength 3.51
  2. Zhijun Zhou · 10 shared papers, 2018–2026 · strength 1.51
  3. Jingxuan Yang · 10 shared papers, 2015–2026 · strength 1.27
  4. Mingyang Liu · 6 shared papers, 2018–2024 · strength 0.74
  5. Xiuhui Shi · 5 shared papers, 2021–2024 · strength 0.68
  6. Yuqing Zhang · 3 shared papers, 2021–2025 · strength 0.67
  7. Hao Yuan · 2 shared papers, 2025–2026 · strength 0.57
  8. Dongfeng Qu · 5 shared papers, 2013–2025 · strength 0.46
  9. Landon L. Moore · 2 shared papers, 2020–2025 · strength 0.43
  10. Hanxiang Zhan · 3 shared papers, 2020–2021 · strength 0.30
  11. Qun Chen · 1 shared paper, 2025 · strength 0.30
  12. Kuirong Jiang · 1 shared paper, 2025 · strength 0.30
  13. Shaobo Zhang · 1 shared paper, 2026 · strength 0.26
  14. Haoran Qi · 1 shared paper, 2026 · strength 0.26
  15. Mingyang Liu · 1 shared paper, 2026 · strength 0.26
  16. Yuqing Zhang · 1 shared paper, 2022 · strength 0.26
  17. Yuqing Zhang · 1 shared paper, 2022 · strength 0.26
  18. Lei Zheng · 2 shared papers, 2018–2024 · strength 0.23
  19. Yumeng Hu · 1 shared paper, 2026 · strength 0.23
  20. Brian K. Dieckgraefe · 2 shared papers, 2011–2022 · strength 0.23
  21. Kumar S. Bishnupuri · 1 shared paper, 2022 · strength 0.20
  22. Nathaniel Weygant · 4 shared papers, 2013–2019 · strength 0.19
  23. Alex Arreola · 1 shared paper, 2024 · strength 0.17
  24. Ryan David Nipp · 1 shared paper, 2024 · strength 0.17
  25. Yuqing Zhang · 1 shared paper, 2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.